Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 14,746 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pulmonary Clear all

Conditions: Acute Respiratory Failure, Covid19
Interventions: Life2000® Ventilator; Device
Lead sponsor: Hill-Rom; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Non-small Cell Lung Cancer
Interventions: Pevonedistat, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy, Chronic Stable Illness
Interventions: Casirivimab+Imdevimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Miami, Florida • Winter Park, Florida

Conditions: Cystic Fibrosis
Interventions: sildenafil, placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Adenocarcinoma of the Lung, Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Squamous Cell Lung Cancer, Stage I Colon Cancer, Stage I Rectal Cancer, Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Colon Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer
Interventions: educational intervention, medical chart review; Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lung Inflammation
Interventions: Cu-DOTA-ECL1i; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lungs; Developmental Disorder
Interventions: 129Xe; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 6 Months
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise; Drug · Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Torrance, California • Jacksonville, Florida

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Marcos, California

Conditions: Pulmonary Vein Stenosis
Interventions: LA transplant; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Pulsed Electromagnetic Field therapy (PEMF), Pulsed Electromagnetic Field Sham therapy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: Fluoxetine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 16 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Interstitial Lung Disease
Interventions: Pirfenidone, Placebo controlled; Drug · Other
Lead sponsor: Evans Fernandez Perez; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions: Cannabidiol, pharmaceutically produced with < 5 ppm THC, Placebo; Drug
Lead sponsor: Cardiol Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Phoenix, Arizona • Cutler Bay, Florida • Miami, Florida + 4 more

Conditions: Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Cirrhosis, Colon Carcinoma, Lung Cancer, Chronic Kidney Disease
Interventions: Values Inventory (VI); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Persistent Infection, Cystic Fibrosis
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • Palo Alto, California • San Franciso, California + 20 more

Conditions: Lung Cancer
Interventions: tipifarnib; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota

Conditions: Atrial Fibrillation
Interventions: Transesophageal Echocardiography; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: COVID-19
Interventions: Caption AI; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Sars-CoV2, COVID
Interventions: Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 6
States / cities: Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more

Conditions: Heart Failure, Pulmonary Disease, Chronic Obstructive, Emphysema, Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: ADAPT Intervention; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Asthma
Interventions: Montelukast, Fluticasone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 51,533 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care

PET Imaging CCR2 in Lung Inflammation

Use of Hyperpolarized 129Xe MR Lung Imaging in Infants

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis

Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

Safety Monitoring of Patients Having Pulmonary Vein Ablation

CAPTION AI to Minimize Risk of COVID Exposure

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

Advancing Symptom Alleviation With Palliative Treatment

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone